Time-invariant system

Optical Encoders Global Market Report 2022: Significant Growth in Adoption of Surgical Robotics in Healthcare Industry Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 29, 2022

The "Optical Encoders Market Research Report by Configuration, Output Signal Format, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Optical Encoders Market Research Report by Configuration, Output Signal Format, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The Global Optical Encoders Market is projected to grow with a significant CAGR in the forecast period.
  • Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities.
  • Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the Global Optical Encoders Market.

Military Vehicle Electrification Market Worth $15.1 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 29, 2022

As the idea of alternate sources like batteries and fuel cells is becoming more popular, the market for military vehicle electrification is expanding.

Key Points: 
  • As the idea of alternate sources like batteries and fuel cells is becoming more popular, the market for military vehicle electrification is expanding.
  • Based on platform, the military vehicle electrification market has been segmented into combat vehicles, support vehicles, and unmanned armored vehicles.
  • The three platforms are anticipated to increase in proportion to the expansion of the military vehicle electrification market.
  • The Military Vehicle Electrification market in Europe is projected to grow at the highest CAGR during the forecast period.

Military Vehicle Electrification Market Worth $15.1 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 29, 2022

As the idea of alternate sources like batteries and fuel cells is becoming more popular, the market for military vehicle electrification is expanding.

Key Points: 
  • As the idea of alternate sources like batteries and fuel cells is becoming more popular, the market for military vehicle electrification is expanding.
  • Based on platform, the military vehicle electrification market has been segmented into combat vehicles, support vehicles, and unmanned armored vehicles.
  • The three platforms are anticipated to increase in proportion to the expansion of the military vehicle electrification market.
  • The Military Vehicle Electrification market in Europe is projected to grow at the highest CAGR during the forecast period.

Cloudian Launches On-Premises Object Storage for Snowflake Analytics Workloads

Retrieved on: 
Tuesday, November 29, 2022

Reflecting Cloudians leadership in object storage, it is the only vendor named a Gartner Peer Insights Customers Choice for Distributed File Systems and Object Storage1 for three consecutive years2.

Key Points: 
  • Reflecting Cloudians leadership in object storage, it is the only vendor named a Gartner Peer Insights Customers Choice for Distributed File Systems and Object Storage1 for three consecutive years2.
  • 2 Gartner, Gartner Peer Insights Voice of the Customer: Distributed File Systems and Object Storage, Peer Contributors, February.
  • Gartner, Gartner Peer Insights Voice of the Customer: Distributed File Systems and Object Storage, Peer Contributors, March 11, 2021.
  • Gartner, Gartner Peer Insights Voice of the Customer: Distributed File Systems and Object Storage, Peer Contributors, April 22, 2022.

Philips debuts new AI-enhanced informatics solutions to increase diagnostic confidence with intelligence at every step of the radiology workflow at RSNA

Retrieved on: 
Monday, November 28, 2022

With simple and more efficient connected workflows, Philips solutions help reduce variability and staff workload, increase productivity, and enhance the patient and physician experience.

Key Points: 
  • With simple and more efficient connected workflows, Philips solutions help reduce variability and staff workload, increase productivity, and enhance the patient and physician experience.
  • At RSNA, Philips will introduce its next-generation Advanced Visualization Workspace platform with AI-enabled algorithms and workflows.
  • Visitors to the Philips booth (#6730) at RSNA will experience the expanded Philips Radiology Workflow , a combination of solutions that support clear and efficient radiology workflows.
  • For additional solutions featured in the Radiology Workflow and spotlighted at RSNA, visit the Philips RSNA Press Backgrounder .

Compucom Named Disruptor in Avasant’s Digital Workplace Services 2022 RadarView

Retrieved on: 
Monday, November 28, 2022

Compucom , a leading IT managed services provider, was recognized as a Disruptor in Avasants Digital Workplace Services 2022 RadarView for the second consecutive year.

Key Points: 
  • Compucom , a leading IT managed services provider, was recognized as a Disruptor in Avasants Digital Workplace Services 2022 RadarView for the second consecutive year.
  • The Avasant Digital Workplace Services 2022 RadarView report noted that as hybrid work is becoming the new normal, businesses are investing in revamping their workplaces to incorporate multiple devices and employee expectations, to eradicate the device compatibility concerns and transform employee experience.
  • With a strong foothold in North America and comprehensive workplace services spanning across verticals, Compucom is poised to disrupt the current digital workplace marketplace, said Swapnil Bhatnagar, research director, Avasant.
  • Compucom provides end-to-end managed workplace services, infrastructure modernization and digital consulting to enable the digital workplace for enterprise, midsize and small businesses.

SambaBox Offers Digital Independence for Powerful Enterprise Directory Management

Retrieved on: 
Monday, November 21, 2022

SambaBox is an enterprise directory solution based on open-source code that provides a cost-effective, stand-alone and powerful corporate alternative meeting global standards.

Key Points: 
  • SambaBox stands out as a global corporate alternative to the now generic Microsoft Active Directory in this category and will be running seamlessly on all cloud platforms soon.
  • Featuring a user-friendly and web-based interface, SambaBox supports different operating systems ranging from Pardus, RedHat, SuSE, Oracle Linux, to Windows and macOS.
  • What sets it apart from its competitors is that since 2017, SambaBox has eliminated single brand dependence, and the need for third-party support.
  • Highlighting that it is this capability that makes it suitable for use in critical projects with information security sensitivity, Ulkuderner said, "SambaBox offers a more responsive solution that goes beyond Microsoft Active Directory, Amazon's sml Directory and Google's directory service which have become generic in this category.

Oxurion Further Improves THR-149 Patent Position

Retrieved on: 
Wednesday, November 23, 2022

With this final decision, Oxurion further improves its intellectual property position over THR-149, its novel therapeutic for the treatment of diabetic macular edema (DME).

Key Points: 
  • With this final decision, Oxurion further improves its intellectual property position over THR-149, its novel therapeutic for the treatment of diabetic macular edema (DME).
  • Oxurion itself holds granted patents for THR-149 through 2034 with the potential to extend through 2039.
  • We are pleased with the Appeal Boards final decision revoking the Dyax claims , said Tom Graney, CEO of Oxurion.
  • We are very proud of our work with THR-149 and removing these claims will assist Oxurion in capturing the long-term value of this important asset.

Ultralife Corporation Names Michael E. Manna President & CEO

Retrieved on: 
Tuesday, November 22, 2022

NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation (Ultralife or the Company) (NASDAQ: ULBI) has appointed Michael E. Manna as the Companys President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company.

Key Points: 
  • NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation (Ultralife or the Company) (NASDAQ: ULBI) has appointed Michael E. Manna as the Companys President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company.
  • In addition to his new role, Mike Manna will retain his leadership position for the Companys Battery & Energy Products segment which he held prior to his appointment as President & CEO.
  • Mr. Whitmore continued, During Mike Popielecs tenure as President & CEO, a succession plan was developed and approved by our Board which is now being implemented with the appointment of Mike Manna.
  • Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems.

Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Retrieved on: 
Tuesday, November 22, 2022

EMERALD-2 (MORF-057-202) is a global phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 in patients with moderate-to-severe ulcerative colitis.

Key Points: 
  • EMERALD-2 (MORF-057-202) is a global phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 in patients with moderate-to-severe ulcerative colitis.
  • The primary endpoint of EMERALD-2 is clinical remission rate as measured by the Modified Mayo Clinic Score (mMCS) at 12 weeks.
  • Following the 12-week induction phase, all patients will receive MORF-057 for 40 weeks of maintenance dosing.
  • Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the 47 integrin for patients with inflammatory bowel disease (IBD).